CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) +1 moredrug
Likely dose
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04199767
NCT04199767Phase 2Completed
CompareCT.gov

SNIFF Multi-Device Study 2 - Study of Nasal Insulin to Fight Forgetfulness

Wake Forest University Health Sciences·interventional·Posted Dec 16, 2019·Updated Apr 2, 2026

In Brief

A Phase 2 clinical trial evaluating 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) and 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) for Mild Cognitive Impairment and Cognitive Impairment. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this study will look at the effects of insulin administered intra-nasally on memory, and on blood levels of insulin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Cognitive Impairment
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 16, 2019
Enrollment StartJul 16, 2020
Primary CompletionNov 3, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.5 years ago

Interventions

20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)drug

Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.

40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)drug

Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.